ECYT : Summary for Endocyte, Inc. - Yahoo Finance

U.S. Markets close in 3 hrs 4 mins

Endocyte, Inc. (ECYT)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.68+0.02 (+0.75%)
As of 12:48 PM EST. Market open.
People also watch:
ACRXINFIEPZMAEGRMACK
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close2.66
Open2.70
Bid2.68 x 700
Ask2.69 x 200
Day's Range2.64 - 2.70
52 Week Range2.55 - 4.35
Volume34,529
Avg. Volume173,446
Market Cap113.28M
Beta1.27
PE Ratio (TTM)-2.65
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswireyesterday

    Mission Therapeutics Appoints Colin Goddard as Chairman

    Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat cancer, neurodegenerative and other diseases, announces that Dr Colin Goddard has been appointed as non-executive Chairman, effective January 1st 2017. Dr Colin Goddard joined the board of Mission Therapeutics as a non-executive Director in July 2015. Michael Moore, Mission's Founder Chairman, will continue on the board and transition to the role of Deputy Chairman.

  • GlobeNewswire5 days ago

    Endocyte to Present at the IASLC 17th World Conference on Lung Cancer

    WEST LAFAYETTE, Ind., Dec. 01, 2016-- Endocyte, Inc., a leader in developing targeted small molecule drug conjugates and companion imaging agents for personalized therapy, today announced that data from ...

  • Capital Cube7 days ago

    ETFs with exposure to Endocyte, Inc. : November 29, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Endocyte, Inc. Here are 5 ETFs with the largest exposure to ECYT-US. Comparing the performance and risk of Endocyte, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)